Market Insight Drug Discovery |

Enabling Challenging Targets: Development Of AS-MS And Integration With Other Screening Technologies

Anselm Schneider

Anselm Schneider

Head of Laboratory in Lead Discovery

Nuvisan

12 August, 2026
Watch time: 18 Minutes

Highlights

Takeaways

Affinity selection-mass spectrometry (AS-MS), combined with orthogonal biophysical methods (HTRF and TSA), provides a powerful platform for identifying binders against challenging targets such as membrane proteins and for protein-protein interactions. Integrated approaches accelerate hit identification and enable the generation of first tool compounds for previously intractable targets.

Anselm Schneider, Head of Laboratory in Lead Discovery, Nuvisan

PREMIUM CONTENT

Want that extra level of detail?
Subscribe and get access to full length presentations and write-ups giving you the insights to stay ahead of the curve.

Please note once we have received payment it can take 24 hours for your account to be updated to the premium access.